Cocrystal Pharma, Inc. · NASDAQ:COCP
Cocrystal Pharma — Investor Presentation (January 2018)
31 slides from Cocrystal Pharma's investor presentation, Jan 8, 2018
Slide 1: Antiviral Therapies Corporate Presentation
C#¥CRYSTAL Antiviral Therapies Paige MA el NC. Corporate Presentation January 2018 OTCQB:COCP www.cocrystalpharma.com
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements, including the NASDAQ uplisting, the anticipated timing of our drug development programs, IND filings, and opportunities in the hepatitis C and influenza antiviral markets. Forward-looking statements also are prefaced b
Slide 3: Corporate Overview
Corporate Overview Clinical Stage Antiviral Company Hepatitis Wholly Owned Product Portfolio Influenza Norovirus Gastroenteritis Proprietary drug discovery platform crystalpharma.com
Slide 4: Investment Highlights
Investment Highlights « Nobel Prize winning expertise leveraged to design first- and best-in-class antiviral drug candidates addressing well established and growing markets + Lead program CC-31244 for the treatment of hepatitis C infection entering Phase 2a - Topline data expected before year end -
Slide 5: Robust Development Pipeline
Robust Development Pipeline Discovery Preclinical Program cc-31244 (Pan-genotypic NS5B NNI) CC-2850 Hepatitis C i ps#enatynicNsse nue) CC-2069 (Pan-genotypic NSSA inhibitor) (CC-42344 (Influenza A PB2 inhibitor) Influenza Influenza A/B inhibitor Norovirus Noro Polymerase Inhibitor www.cocrystalpharm
Slide 6: Seasoned Management Team
Seasoned Management Team Gary Wilcox, Ph.D. Vice Chairman and Interim Chief Executive Officer Over 35 years of executive biotech leadership experience and played a key role in the development of Cialis Cialis: tadalafil Sam Lee, Ph.D. President 20 years of anti-infective drug discovery research expe
Slide 7: Board of Directors
Board of Directors Raymond F..Sehinazi, Frances Winship Walters Professor of Pediatrics, Director, Laboratory of Biochemical Ph.D Pharmacology and Director, HIV Cure Scientific Working Group at Emory University Chairman Gary Wilcox, Ph.D. Vice Chairman and Interim Vice Chairman and Interim Chief Exe
Slide 8: Scientific Advisors
Scientific Advisors Roger Kornberg, Ph.D. Professor of Structural Biology at Stanford University School of Medicine. Nobel Laureate in Chief Scientist, Chainrmanof Chemistry, Member of the National Academy of Sciences, and the American Academy of Arts and Scientific Advisory Board Sciences Stanford
Slide 9: Cocrystal Technology
Cocrystal Technology Nobel Prize Winning Technology | Near atomic resolution, “ X-ray quality crystal production “ Drug pocket selection « Hit-to-lead process ~ Lead optimization www.cocrystalpharma.com
Slide 10: CC-31244: Broad Spectrum HCV NNI
CC-31244: Broad Spectrum HCV NNI Demonstration of Cocrystal’s Enabling Technology HCV GT1 — GT6 NSSB polymerase crystals HCV NS5B polymerase Proven track record for broad spectrum antiviral leads Cc NS (e RYS TA L www.cocrystalpharma.com
Slide 11: Hepatitis C Treatment Market Share
Hepatitis C Treatment Market Share Nine Months Ended September 30, 2017 Sales, $10.25 Billion = Gilead (Harvoni, Epclusa, Sovaldi, Vosevi) m J&J (Olysio) mAbbVie (Viekira, Mavyret) Gilead $7.64 B ™ Merck (Zepatier) Source: 2017 10-Q. quarterly filings for period ending September 30, 2017 www.cocryst
Slide 12: Abbvie's Mavyret Demonstrated a Shorter Treatment
Abbivie’s Mavyret Demonstrated a Shorter Treatment: From 12 Weeks To 8 Weeks Approved broad spectrum HCV combination therapy Nuc + NSSA inhibitor PI + NSSA inhibitor Gilead’s EPCLUSA Abbivie’s Mavyret (sofosbuvir 400mg/ (glecaprevir 100 mg/ velpatasvir 100 mg) pibrentasvir 40 mg) 12 weeks treatment
Slide 13: Cocrystal's HCV Strategy: Shorter Combination Therapy
Cocrystal’s HCV Strategy: Shorter Combination Therapy Multiple opportunities in developing shorter combination therapy with approved HCV drugs NSSA Inhibitor S) CC-31244 NS5B NNI fs NS5B Nuc => 2 or 3 broad spectrum O drugs for shorter therapy NS3 Protease Inhibitor www.cocrystalpharma.com
Slide 14: Next Wave Cocrystal's Combination Therapy
Next Wave Cocrystal’s Combination Therapy: CC-31244 with Approved HCV Drugs * Potential best-in-class HCV NNI with a strong profile - Broad spectrum, potent NSS5B polymerase inhibitor Developed by Cocrystal’s proprietary structure-based discovery platform High barrier to drug resistance Effective ag
Slide 15: Phase 1a Study Completed
Phase 1a Study Completed s 2 20 mg 50 mg, 100mg 200mg* | 400mg Single ascending doses (complete) = N = 40; 30 CC-31244, 10 placebo; * food effect assessed Multiple ascending doses => 200 mg BID 400 mg QD (complete) N = 16; 12 CC-31244, 4 placebo x 7 days Endpoints ° Safety: adverse events (AEs) and
Slide 16: Phase 1b Study Completed
Phase 1b Study Completed 200 mg BID x7 days Status N = 4; 3 CC-31244,1 placebo Complete HCV GT1 | HCV RNA2 5 log, .|U/ml Naive 400 mg QD x 7 days Status | N = 5; 4 CC-31244, 1 placebo Complete Single doses 1 QD or BID x7 days N = 5; 4 CC-31244, 1 placebo Complete Endpoints ° Efficacy: changes in HCV
Slide 17: Superior Viral Load Reduction
Superior Viral Load Reduction * HCV RNA viral load decline of 3 logs by 48 hours « After the NNI treatment, the viral load levels were slowly increased Mean Viral Load Change From Baseline os (CC-31244 at 400 mg QD or 200 mg BID x7 days) ———————————————————— 01 =e CC-31244 No CC-31244 “a 400 mg QD 4
Slide 18: Best-in-Class Potential of Any NNI
Best-in-Class Potential of Any NNI Dose Treatment se lleete) Drug Genotype mn Duration (dave reduction (mg) (days) (Log,olU/ml) CC-31244 @ Genotype1-6 @ 400 @ 7 (QD) -3.0 ABT-333* (Dasabuvir) Genotype 1 400 3 (BID) -1.08 800 3 (BID) -0.95 GS-9190 (Tegobuvir) Genotype 1 40 3 (BID) -1.0 120 3 (BID) 45
Slide 19: CC-31244 Phase 2a Study Plan
CC-31244 Phase 2a Study Plan = An open-label, Phase 2a study evaluating the safety, tolerability and preliminary efficacy of CC-31244 with approved HCV DAAs CC-31244 (400 mg) QD + Approved DAAs => 2 weeks treatment = Endpoints - Efficacy: changes in HCV RNA viral load and uRVR (ultra rapid virologic
Slide 20: HCV Summary and Conclusion
HCV Summary and Conclusion * Showed an acceptable safety profile in both healthy volunteers and GT1 patients up to 400 mg x 7 days * No serious adverse events or discontinuations due to adverse events * Demonstrated HCV RNA viral load reduction of ~ 3 logs by 48 hours * Demonstrated a sustained post
Slide 21: New Antivirals For Influenza
New Antivirals For Influenza * High mortality rate: - 1918 Spanish Flu, 20-100 million deaths - 1957 Asian Flu, 1-1.5 million deaths - 1968 Hong Kong Flu, 0.75-1 million deaths - 2009 Swine Flu, 0.15-0.5 million deaths * Emerging influenza viruses - Highly virulent avian influenza viruses - Tamiflu-
Slide 22: Great Opportunity in Influenza Antiviral Market
Great Opportunity in Influenza Antiviral Market * Seasonal and pandemic infection - 3-5 million cases of severe illness per year - 250,000 — 500,000 deaths worldwide* * Approved influenza therapies has major limitation * Multiple product routes of delivery, inhalation, oral, and intravenous (IV) * S
Slide 23: Influenza: Still Significant Unmet Need
Influenza: Still Significant Unmet Need Antiviral Developer Oseltamivir Gilead/ Oral neuraminidase (Tamiflu) Genentech Inhibitor/75 mg bid for five days Zanamivir Biota/ Inhaled neuraminidase inhibitor/ (Relenza) GSK 5 mg inhalation bid for five days Peramivir Biocryst/ A single-dose intravenous neu
Slide 24: Properties Of Cocrystal Influenza Antivirals
Properties Of Cocrystal Influenza Antivirals * Superior pharmacological properties - Broad spectrum against pandemic and seasonal influenza strains - Efficacious against neuraminidase inhibitor (Tamiflu) resistant strains - Novel mechanism of action « Flexible drug administration routes * Satisfacto
Slide 25: Influenza A Preclinical Lead CC-42344
Influenza A Preclinical Lead CC-42344 Influenza Crystals Potent and favorable PK profiles CC-42344 Excellent anti-influenza activity against pandemic, . seasonal, and Tamiflu resistant influenza strains Binds a highly conserved site Novel mechanism of action IND filing scheduled in 2018 www.cocrysta
Slide 26: Early Stage Programs
Early Stage Programs ¢ Influenza A/B inhibitor program - Influenza cocrystals developed - Structure-based lead discovery ongoing - IND filing in 2019 ¢ Noro Polymerase Inhibitor - Structure-based NNI discovery ongoing - Multiple polymerase crystals developed - Noro nucleoside lead discovery ongoing
Slide 27: Cocrystal-HitGen-InterX Collaboration
Cocrystal-HitGen-InterX Collaboration: Aimed at Rapid Lead Discovery Process Gm osm * Combines synergistic drug discovery platforms developed by Cocrystal/HitGen/InterxX * Break-through hit-to-lead process * High quality novel leads will be developed CBC RYST L www.cocrystalpharma.com
Slide 28: Financial Snapshot
Financial Snapshot — OTCQB: COCP $146MM 728MM 130K Market cap* Common shares 3 month average outstanding daily volume* www.cocrystalpharma.com
Slide 29: Capitalization Table
Capitalization Table *Options Common & Beneficial Holders Stock % |Warrants/|Total % Directors and Executive Officers} 434M 60%| 5.8M 440M 58% 5% Holders and Insiders 78M 11%| 1.0M 79M 11% Others 216M 29%| 20.8M 237M 31% Total 728M 100%| 27.6M 756M | 100% * Based on 21.3M options and 6.3M warrants o
Slide 30: Near-Term Milestones Expected to Drive Value
Near-Term Milestones Expected to Drive Value HVC CC-31244: * Commence patient enrollment in Phase 2a study HVC CC-31244: * Commence patient dosing in Phase 2a study HCV CC-31244: * Complete Phase 2a study Influenza CC-42344: * Complete preclinical IND-enabling studies HCV CC-31244: + Announce Phase
Slide 31: Thank You!
C¥CRYSTAL PHARMA, IN Thank You! OTCQB:COCP www.cocrystalpharma.com
Cocrystal Pharma — Investor Presentation (January 2018) on 6ix